ASP Isotopes Inc. entered into Series Seed-1 Preferred Stock Purchase Agreement with Opeongo, Inc. valued at $2.2952 per share (effective 2026-01-26).
“On January 26, 2026, ASP Isotopes Inc., a Delaware corporation (“ ASP Isotopes ” or the “ Company ”), entered into a Series Seed-1 Preferred Stock Purchase Agreement (the “ Purchase Agreement ”) with Opeongo, Inc., a Delaware corporation (“ Opeongo ”), pursuant to which the Company agreed to purchase from Opeongo 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock, $0.0001 par value per share (the “ Series Seed-1 Preferred Stock ”), at a price of $2.2952 per share”
M&A Transactions
ASP Isotopes Inc. completed an acquisition involving Renergen Limited (closed 2026-01-06).
“On the Closing Date, ASP Isotopes acquired all of the issued Renergen Ordinary Shares from Renergen shareholders in exchange for shares of Company Common Stock at an exchange ratio of 0.09196 shares of Company Common Stock for each Renergen Ordinary Share (the “Consideration Shares”) through the implementation of the Scheme, resulting in the issuance of an aggregate of 14,270,000 Consideration Shares.”
Material Agreements
ASP Isotopes Inc. amended a credit facility with Renergen (effective 2025-11-27).
“on November 27, 2025, the Company, ASP Isotopes South Africa Proprietary Limited (“ASPI South Africa”) and Renergen entered into an amendment to the Term Loan Facility Agreement, dated May 19, 2025, by and among the Company, ASP Isotopes South Africa, as lender, and Renergen, as borrower, to extend the final repayment date thereunder to January 30, 2026.”
Material Agreements
ASP Isotopes Inc. amended a merger with Renergen Limited (effective 2025-11-27).
“On November 27, 2025, ASP Isotopes Inc. (the “Company” or “ASP Isotopes”) and Renergen Limited (“Renergen”), a South African company listed on the exchange operated by the JSE Limited and the Australian Securities Exchange, entered into a letter agreement to extend the date for the fulfillment of the conditions to the previously announced offer by the Company to acquire 100% of the ordinary shares (excluding treasury shares) of Renergen, pursuant to a scheme of arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the “Scheme”).”
Equity Issuances
ASP Isotopes Inc. issued convertible note to certain institutional and individual investors for approximately $64.3 million.
“On November 7, 2025, Quantum Leap Energy LLC (“QLE”), a wholly owned subsidiary of ASP Isotopes Inc. (“ASPI”), entered into a Convertible Note Purchase Agreement (the “Purchase Agreement”) with certain institutional and individual investors (collectively, the “Purchasers”), to issue and sell to the Purchasers convertible promissory notes of QLE (the “QLE 2025 Notes”) in an offering to accredited investors under Regulation D or Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or investors who are not a person in the United States or a U.S. Person (within the meaning of Rule 902(k) of Regulation S promulgated under the Securities Act) for approximately $64.3 million of QLE 2025 Notes.”
Debt Financings
ASP Isotopes Inc. incurred convertible notes of $64.3 million with certain institutional and individual investors at 8.0% per annum maturing five-year anniversary of the initial closing.
“investors who are not a person in the United States or a U.S. Person (within the meaning of Rule 902(k) of Regulation S promulgated under the Securities Act) for approximately $64.3 million of QLE 2025 Notes. The initial closing of the offering is expected to be on or about November 17 or 18, 2025, subject to satisfaction of customary closing conditions, and at such”
Sipho Maseko was appointed as Director at ASP Isotopes Inc..
“the Board appointed Sipho Maseko as director”
Hendrik Strydom departed as Director at ASP Isotopes Inc..
“Dr. Hendrik Strydom, PhD, Chief Technology Officer of the Company, stepped down as a member of the board of directors of the Company”
Robert Ainscow departed as Chief Operating Officer at ASP Isotopes Inc..
“Mr. Ainscow will resign as the Company’s Chief Financial Officer as of the Start Date and will continue in his role as Chief Operating Officer.”
Heather Kiessling was appointed as Chief Financial Officer at ASP Isotopes Inc..
“On June 10, 2024, the Board of Directors (the “Board”) of ASP Isotopes Inc. (the “Company”) appointed Heather Kiessling as the Chief Financial Officer of the Company, effective as of July 1, 2024”
Material Agreements
ASP Isotopes Inc. entered into Inducement Agreement with a certain holder (the "Holder") of warrants to purchase shares of the Company’s common stock valued at aggregate gross proceeds of approximately $5.5 million (effective 2024-04-09).
“On April 9, 2024, ASP Isotopes Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with a certain holder (the “Holder”) of warrants to purchase shares of the Company’s common stock”
Material Agreements
ASP Isotopes Inc. entered into Placement Agent Agreement with Ocean Wall Limited valued at fee equal to 5.0% of the gross proceeds, 50% cash and 50% convertible promissory note (effective 2024-02-29).
“The Company and QLE engaged Ocean Wall Limited (the “Placement Agent”) to act as QLE’s sole placement agent in connection with the offering of QLE Notes, pursuant to a placement agency agreement (the “Placement Agent Agreement”), dated as of February 29, 2024, between the Company, QLE and the Placement Agent.”
Material Agreements
ASP Isotopes Inc. entered into Convertible Note Purchase Agreement with certain institutional and individual investors valued at gross proceeds of approximately $20.5 million (effective 2024-02-29).
“On February 29, 2024, Quantum Leap Energy LLC (“QLE”), a wholly owned subsidiary of ASP Isotopes Inc. (the “Company” or “we”), entered into a Convertible Note Purchase Agreement (the “Purchase Agreement”) with certain institutional and individual investors (collectively, the “Purchasers”), to issue and sell to the Purchasers convertible promissory notes of QLE (the “QLE Notes”) in an offering to non-U.S. persons outside of the United States under Regulation S of the Securities Act of 1933, as amended (the “Securities Act”).”
Rob Ryan was appointed as director at ASP Isotopes Inc..
“Effective January 14, 2024, the Board appointed Rob Ryan as director, to fill the vacancy on the Board created by the resignation of Mr. Donfeld.”
Joshua Donfeld resigned as director at ASP Isotopes Inc..
“On January 12, 2024, Joshua Donfeld, a member of the board of directors (the “Board”) of ASP Isotopes Inc. (the “Company”), provided notice to the Company of his decision to voluntarily step down from the Board, effective immediately.”
Shareholder Votes
ASP Isotopes Inc. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-04 meeting.
“The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 23,225,300 27,328 24,557”
Shareholder Votes
ASP Isotopes Inc. shareholders approved Election of Class I Directors at the 2023-12-04 meeting.
“The Company’s stockholders elected the following two Class I Directors to hold office until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified. Name Votes For Votes Withheld Broker Non-Votes Paul Mann 18,699,866 46,160 4,531,159 Joshua Donfeld 18,588,449 157,577 4,531,159”
Material Agreements
ASP Isotopes Inc. entered into Share Purchase Agreement with Nucleonics Imaging Proprietary Limited valued at USD 2,000,000 for 51% of PET Labs shares, with option for remaining 49% for USD 2,200,000 (effective 2023-10-30).
“On October 30, 2023, ASP Isotopes Inc. (the “Company”) entered into a Share Purchase Agreement (the “Purchase Agreement”) with Nucleonics Imaging Proprietary Limited, a company incorporated in the Republic of South Africa (“Seller”), relating to the purchase and sale of ordinary shares in the issued share capital of Pet Labs Pharmaceuticals Proprietary Limited, a company incorporated in the Republic of South Africa (“PET Labs”).”
Professor Mike Gorley was appointed as Director at ASP Isotopes Inc..
“the Board appointed Professor Mike Gorley to serve as a director of the Company, effective immediately following Mr. Vasnetsov’s resignation.”
Sergey Vasnetsov resigned as Director at ASP Isotopes Inc..
“On October 19, 2023, Sergey Vasnetsov provided notice to the Company of his decision to voluntarily step down from the Company’s board of directors, effective October 23, 2023.”
Material Agreements
ASP Isotopes Inc. entered into Securities Purchase Agreements with certain institutional and other accredited investors and certain directors of the Company valued at approximately $9.1 million (effective 2023-10-09).
“On October 9, 2023 and October 10, 2023, ASP Isotopes Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain institutional and other accredited investors and certain directors of the Company (collectively, the “Purchasers”), pursuant to which the Company has agreed to issue and sell an aggregate of 9,952,510 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), for aggregate cash consideration of approximately $9.1 million”
Listing & Compliance Notices
ASP Isotopes Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
“May 5, 2023, ASP Isotopes Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price Requirement”). The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company’s common s”
Material Agreements
ASP Isotopes Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at a total cash fee equal to 7.0% of the aggregate gross proceeds of the Offering (effective 2023-02-15).
“The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as the Company’s exclusive placement agent in connection with the Offering, pursuant to the engagement letter (the “Engagement Letter”), dated as of February 15, 2023, between the Company and the Placement Agent.”
Material Agreements
ASP Isotopes Inc. entered into Securities Purchase Agreement with a single institutional investor valued at approximately $5 million (effective 2023-03-14).
“On March 14, 2023, ASP Isotopes Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Purchaser”)”
Material Agreements
ASP Isotopes Inc. entered into Underwriting Agreement with Revere Securities LLC (effective 2022-11-09).
“On November 9, 2022, ASP Isotopes Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Revere Securities LLC, as representative of the several underwriters identified therein (the “Underwriters”), relating to the public offering (the “Offering”) of 1,250,000 shares of the Company’s common stock (the “Shares”) by the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.